RxDoctor Payments Data

Melissa Peters, DO

Internal Medicine · Centennial, CONPI 1609839786

Payments from drug & device makers

$7,634in general payments, 2019–2025

Across 395 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$668
  • AstraZeneca$605
  • Novo Nordisk$562
  • Amgen$519
  • GSK$329
  • plus $4K from 48 others

What the payments were for

  • Food & beverage$7,622100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,634 in reported general payments places this provider in the 95th percentile of 1,430 internal medicine providers in Colorado.

See all internal medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$113,276
Medicare patients
278
Services billed
2,512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban75$110,947
OzempicSemaglutide50$63,831
MounjaroTirzepatide42$46,267
MyrbetriqMirabegron50$39,956
XareltoRivaroxaban24$32,353
RybelsusSemaglutide16$17,313
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$16,618
Mirtazapine241$8,418
Spiriva RespimatTiotropium Bromide12$8,263
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$7,200
GemtesaVibegron11$6,739
LantusInsulin Glargine,hum.Rec.Anlog17$6,113
SynthroidLevothyroxine Sodium83$5,739
Levothyroxine Sodium587$5,634
Atorvastatin Calcium513$3,886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$668$110,94775 claims
Novo NordiskOzempic, Rybelsus$562$81,14466 claims
Lilly USA, LLCMounjaro$321$46,26742 claims
Astellas Pharma US IncMyrbetriq$258$39,95650 claims
GSKTrelegy Ellipta$329$16,61811 claims
Boehringer IngelheimSpiriva Respimat$104$8,26312 claims
Sumitomo Pharma America, Inc.Gemtesa$108$6,73911 claims
Sanofi-aventis U.S. LLCLantus$124$6,11317 claims
AbbVieSynthroid$1,154$5,73983 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,430 internal medicine providers in Colorado.

Other internal medicine in Centennial

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →